Pacific Edge appoints Simon Flood as chairman designate, aiming to leverage his global investment expertise to navigate Medicare reimbursement challenges for its bladder cancer diagnostic tests in the US.
- Simon Flood appointed Director and Chairman Designate
- Chris Gallaher to retire after nine years of leadership
- Focus on regaining Medicare reimbursement for Cxbladder tests
- Inclusion of Cxbladder Triage in American Urological Association guidelines
- Upcoming Medicare expert panel review in February 2026
Leadership Transition at Pacific Edge
Pacific Edge, a global player in bladder cancer diagnostics, has announced a significant leadership change with the appointment of Simon Flood as Director and Chairman Designate. Flood will officially take over as Chairman following the board meeting on 18 December 2025, succeeding Chris Gallaher, who has led the company through a challenging period and is now stepping down after nine years.
Flood brings a rich background in investment management and governance, having held senior roles across London, Hong Kong, and Singapore. His experience spans major firms such as Mercury Asset Management and Merrill Lynch Investment Managers, as well as leadership positions in New Zealand’s corporate and public sectors. This global perspective is expected to be instrumental as Pacific Edge navigates its next phase.
Strategic Focus on Medicare Reimbursement
The timing of Flood’s appointment aligns closely with Pacific Edge’s pressing objective – regaining Medicare reimbursement for its flagship Cxbladder diagnostic tests in the United States. The company has faced restrictive Medicare coverage decisions that have constrained growth, but recent developments offer a glimmer of optimism.
Notably, Cxbladder Triage has been included in the 2025 revision of the American Urological Association’s Microhematuria Guideline, a milestone that signals growing clinical acceptance. Furthermore, the Medicare Administrative Contractor Novitas is set to convene an expert panel in February 2026 to review the evidence supporting Cxbladder’s clinical utility, a step that often precedes new or revised Medicare coverage determinations.
Outlook and Market Implications
Pacific Edge’s leadership transition comes at a pivotal moment. With Flood’s expertise in scaling innovative technology businesses and capital markets, the company is positioning itself to capitalize on the evolving regulatory landscape. CEO Dr Peter Meintjes and the board appear confident that overcoming Medicare’s current restrictions will unlock renewed growth potential.
Meanwhile, outgoing Chairman Gallaher expressed strong confidence in the company’s future, highlighting the stability and shareholder value created during his tenure. The board’s gratitude for his leadership underscores the significance of this transition as Pacific Edge prepares for its next chapter.
Bottom Line?
Simon Flood’s appointment signals a strategic pivot as Pacific Edge aims to convert clinical validation into Medicare coverage and market growth.
Questions in the middle?
- Will the February 2026 Medicare expert panel recommend expanded coverage for Cxbladder tests?
- How will Simon Flood’s leadership influence Pacific Edge’s US market strategy and investor relations?
- What are the potential timelines and financial impacts if Medicare reimbursement is reinstated?